See more : Shandong Shuangyi Technology Co., Ltd. (300690.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of United Therapeutics Corporation (UTHR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- InterDigital, Inc. (0U3Q.L) Income Statement Analysis – Financial Results
- Tortoise Power and Energy Infrastructure Fund, Inc. (TPZ) Income Statement Analysis – Financial Results
- Alpha Professional Holdings Limited (0948.HK) Income Statement Analysis – Financial Results
- AP Holdings Co.,Ltd. (3175.T) Income Statement Analysis – Financial Results
- Delta Resources Limited (DTARF) Income Statement Analysis – Financial Results
United Therapeutics Corporation (UTHR)
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.60B | 1.47B | 1.29B | 1.12B | 916.08M | 743.18M | 603.83M | 369.85M | 281.50M | 210.94M | 159.63M | 115.92M | 73.59M | 53.34M | 30.12M | 5.73M | 2.05M | 400.00K | 100.00K |
| Cost of Revenue | 257.50M | 146.70M | 122.50M | 108.10M | 117.60M | 198.70M | 105.70M | 72.70M | 69.04M | 125.88M | 131.13M | 119.30M | 88.90M | 73.47M | 45.32M | 30.07M | 22.26M | 17.03M | 12.32M | 8.25M | 6.78M | 5.46M | 3.14M | 1.71M | 1.40M | 0.00 |
| Gross Profit | 2.07B | 1.79B | 1.56B | 1.38B | 1.33B | 1.43B | 1.62B | 1.53B | 1.40B | 1.16B | 985.86M | 796.78M | 654.28M | 530.37M | 324.53M | 251.43M | 188.68M | 142.60M | 103.60M | 65.34M | 46.56M | 24.66M | 2.59M | 343.47K | -1.00M | 100.00K |
| Gross Profit Ratio | 88.94% | 92.42% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% | 95.29% | 90.23% | 88.26% | 86.98% | 88.04% | 87.83% | 87.75% | 89.32% | 89.45% | 89.33% | 89.38% | 88.79% | 87.28% | 81.89% | 45.27% | 16.76% | -250.00% | 100.00% |
| Research & Development | 408.00M | 322.90M | 540.10M | 357.70M | 1.18B | 357.90M | 264.60M | 147.60M | 245.10M | 242.55M | 299.35M | 173.39M | 180.02M | 166.76M | 122.19M | 239.18M | 83.35M | 57.57M | 36.05M | 30.60M | 35.42M | 26.78M | 32.59M | 70.19M | 30.70M | 11.00M |
| General & Administrative | 395.30M | 416.20M | 402.60M | 369.00M | 275.50M | 206.70M | 265.80M | 232.20M | 358.32M | 299.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.44M | 16.94M | 11.74M | 5.00M | 0.00 |
| Selling & Marketing | 81.80M | 70.80M | 64.40M | 54.90M | 60.70M | 59.10M | 64.30M | 84.60M | 94.30M | 82.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.45M | 3.38B | 0.00 | 0.00 | 0.00 |
| SG&A | 477.10M | 487.00M | 467.00M | 423.90M | 336.20M | 265.80M | 330.10M | 316.80M | 452.61M | 381.29M | 394.01M | 201.75M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 54.03M | 24.66M | 21.53M | 22.67M | 15.89M | 16.94M | 11.74M | 5.00M | 2.40M |
| Other Expenses | 0.00 | -40.20M | 42.20M | 49.30M | 22.60M | -7.70M | 13.20M | 2.40M | 157.00K | 3.97M | 635.00K | 31.87M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 56.05M | 24.66M | 21.53M | 22.67M | 15.89M | 0.00 | -79.74K | -1.30M | 2.40M |
| Operating Expenses | 885.10M | 809.90M | 1.01B | 781.60M | 1.52B | 623.70M | 594.70M | 464.40M | 697.71M | 623.84M | 693.36M | 375.13M | 336.50M | 366.36M | 298.53M | 333.49M | 182.38M | 113.62M | 60.71M | 52.13M | 58.08M | 42.67M | 49.53M | 81.84M | 34.40M | 13.40M |
| Cost & Expenses | 1.14B | 956.60M | 1.13B | 889.70M | 1.64B | 822.40M | 700.40M | 537.10M | 766.75M | 749.72M | 824.49M | 494.43M | 425.40M | 439.83M | 343.85M | 363.55M | 204.64M | 130.65M | 73.02M | 60.38M | 64.87M | 48.12M | 52.67M | 83.55M | 35.80M | 13.40M |
| Interest Income | 162.70M | 45.20M | 16.70M | 28.60M | 44.20M | 28.60M | 10.90M | 3.50M | 0.00 | 0.00 | 3.83M | 3.94M | 3.45M | 2.94M | 5.15M | 11.03M | 13.60M | 10.70M | 5.36M | 2.99M | 2.44M | 4.95M | 10.02M | 10.69M | 0.00 | 0.00 |
| Interest Expense | 59.30M | 32.40M | 18.60M | 23.50M | 44.20M | 13.90M | 9.00M | 3.90M | 4.74M | 17.59M | 18.06M | 16.64M | 21.37M | 19.71M | 12.88M | 16.00K | 2.18M | 482.00K | 29.00K | 4.00K | 112.00K | 117.00K | 172.72K | 120.04K | 0.00 | 0.00 |
| Depreciation & Amortization | 53.20M | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M | 31.00M | 31.60M | 32.92M | 32.25M | 31.26M | 27.15M | 20.54M | 17.92M | 11.39M | 4.54M | 957.00K | 1.46M | 2.41M | 2.28M | 2.33M | 3.14M | 3.51M | -79.74K | -1.30M | -500.00K |
| EBITDA | 1.39B | 1.04B | 736.80M | 646.30M | -74.90M | 838.40M | 1.05B | 1.09B | 1.08B | 575.02M | 323.76M | 484.46M | 341.02M | 185.47M | 43.04M | -67.75M | 22.19M | 28.98M | 50.09M | 17.83M | -9.20M | -14.87M | -43.42M | -81.58M | -36.66M | -13.80M |
| EBITDA Ratio | 59.58% | 50.85% | 36.48% | 45.27% | -8.34% | 50.76% | 60.17% | 66.56% | 47.70% | 42.12% | 26.59% | 52.88% | 43.21% | 27.62% | 8.38% | -25.31% | 3.83% | 19.59% | 39.04% | 20.98% | -17.60% | -15.25% | -754.18% | -3,752.55% | -9,200.00% | -13,800.00% |
| Operating Income | 1.18B | 979.70M | 555.90M | 593.60M | -187.60M | 805.40M | 814.90M | 1.06B | 699.02M | 538.80M | 292.50M | 421.65M | 317.78M | 164.01M | 26.00M | -82.06M | 6.30M | 28.98M | 42.89M | 13.21M | -11.53M | -18.00M | -46.94M | -81.50M | -35.40M | -13.30M |
| Operating Income Ratio | 50.91% | 50.60% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 27.16% | 7.03% | -29.15% | 2.99% | 18.16% | 37.00% | 17.95% | -21.61% | -59.77% | -818.93% | -3,977.08% | -8,850.00% | -13,300.00% |
| Total Other Income/Expenses | 89.40M | -29.10M | 38.00M | 45.30M | 22.60M | -46.50M | -45.40M | -1.50M | 345.42M | -13.60M | -13.60M | 19.03M | -18.67M | -16.17M | -7.23M | 9.76M | 10.28M | 10.93M | 4.63M | 2.24M | 1.56M | -5.65M | 9.65M | -4.68M | 63.50K | 546.20K |
| Income Before Tax | 1.27B | 950.60M | 593.90M | 638.90M | -165.00M | 758.90M | 769.50M | 1.06B | 1.04B | 525.18M | 278.90M | 440.67M | 299.12M | 147.84M | 18.77M | -72.30M | 16.58M | 39.91M | 47.52M | 15.45M | -9.97M | -23.65M | -37.29M | -86.18M | -35.30M | -12.80M |
| Income Before Tax Ratio | 54.75% | 49.09% | 35.24% | 43.07% | -11.39% | 46.62% | 44.60% | 66.31% | 71.26% | 40.76% | 24.97% | 48.10% | 40.25% | 24.48% | 5.07% | -25.68% | 7.86% | 25.00% | 41.00% | 20.99% | -18.69% | -78.52% | -650.55% | -4,205.51% | -8,825.00% | -12,800.00% |
| Income Tax Expense | 289.50M | 223.30M | 118.10M | 124.10M | -60.50M | 169.70M | 351.60M | 346.50M | 392.80M | 185.11M | 104.34M | 136.23M | 81.87M | 41.92M | -695.00K | -29.51M | -3.28M | -34.06M | -17.49M | -3.03M | -2.51M | 5.44M | -9.65M | -5.89M | -1.90M | 0.00 |
| Net Income | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M | 651.64M | 340.07M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.50M | -12.80M |
| Net Income Ratio | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.20% | 24.22% | 44.64% | 44.46% | 26.39% | 15.63% | 33.23% | 29.32% | 17.54% | 5.26% | -15.20% | 9.41% | 46.33% | 56.09% | 20.99% | -18.69% | -78.52% | -650.55% | -3,689.55% | -8,375.00% | -12,800.00% |
| EPS | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 | 14.17 | 7.06 | 3.49 | 5.84 | 3.81 | 1.89 | 0.37 | -0.93 | 0.47 | 1.61 | 1.43 | 0.36 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| EPS Diluted | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 | 12.72 | 6.28 | 3.28 | 5.71 | 3.67 | 1.78 | 0.35 | -0.93 | 0.44 | 1.53 | 1.29 | 0.33 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| Weighted Avg Shares Out | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M | 43.50M | 44.00M | 43.80M | 46.00M | 48.18M | 50.08M | 52.09M | 57.16M | 56.14M | 53.31M | 45.80M | 42.45M | 46.02M | 45.65M | 43.45M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
| Weighted Avg Shares Out (Dil) | 49.70M | 48.50M | 47.30M | 44.60M | 43.80M | 44.00M | 44.90M | 46.80M | 51.22M | 54.16M | 53.23M | 53.28M | 59.40M | 59.52M | 56.13M | 45.80M | 44.90M | 48.28M | 50.41M | 46.70M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?
United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy
United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom
United Therapeutics: One To Believe In Despite Competitive Threats
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?
United Therapeutics Q3 Earnings & Sales Beat Estimates
United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings
Source: https://incomestatements.info
Category: Stock Reports